Bantam Pharmaceutical

About Bantam Pharmaceutical

Bantam Pharmaceutical is a clinical-stage biopharmaceutical firm, established in 2015, that is concentrated on creating a new class of cancer treatments. The company's scientific approach is centered on the selective modulation of mitochondrial dynamics, a strategy designed to induce apoptosis, or programmed cell death, specifically in cancerous cells while leaving normal cells unharmed. Bantam's operations are based in the Alexandria cluster in Research Triangle Park, North Carolina, an area known for its clinical development resources.

The company was initially led by founding CEO Dr. Mike Luther, who was succeeded in 2021 by Michael Stocum. Stocum, who joined in late 2019 as Chief Business Officer, brings over 25 years of experience in the pharmaceutical and biotech industries, including roles at Organon (now Merck) and GlaxoSmithKline. His background includes founding Personalized Medicine Partners and serving as the founding CEO of Inivata, a clinical cancer genomics company. This experience in oncology product development and building early-stage companies is directly relevant to his leadership at Bantam as it transitions from discovery to clinical development.

The company's lead product candidate is BTM-3566, an orally administered small molecule therapeutic. This drug targets a range of difficult-to-treat hematological and solid tumors. Its initial clinical focus is on B-cell malignancies such as mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL). The mechanism of action for BTM-3566 involves activating the mitochondrial protease OMA1, which in turn initiates a stress response pathway (ATF4-Integrated Stress Response) that leads to cancer cell death. Preclinical studies have shown significant anti-cancer activity, with BTM-3566 causing substantial tumor regression—and in some cases, complete elimination—in models resistant to standard treatments. The company holds an active Investigational New Drug (IND) application in the U.S. and a Clinical Trial Application (CTA) in Canada, with a Phase 1 clinical trial for BTM-3566 underway.